Insider Transactions in Q4 2021 at Aprea Therapeutics, Inc. (APRE)

Date	Insider	Transaction	Ownership Type	Shares Traded	Value / Price
Dec 01 2021	Gregory Alan Korbel SVP, Chief Operating Officer	SELL Open market or private sale	Direct	27,500 -61.57%	$82,500 $3.96 P/Share
Dec 01 2021	Gregory Alan Korbel SVP, Chief Operating Officer	BUY Exercise of conversion of derivative security	Direct	27,500 +38.11%	$0 $0.92 P/Share
Nov 01 2021	Gregory Alan Korbel SVP, Chief Operating Officer	SELL Open market or private sale	Direct	27,500 -61.57%	$137,500 $5.0 P/Share
Nov 01 2021	Gregory Alan Korbel SVP, Chief Operating Officer	BUY Exercise of conversion of derivative security	Direct	27,500 +38.11%	$0 $0.92 P/Share
Oct 01 2021	Gregory Alan Korbel SVP, Chief Operating Officer	SELL Open market or private sale	Direct	27,500 -61.57%	$110,000 $4.89 P/Share
Oct 01 2021	Gregory Alan Korbel SVP, Chief Operating Officer	BUY Exercise of conversion of derivative security	Direct	27,500 +38.11%	$0 $0.92 P/Share
Oct 01 2021	Lars B. Abrahmsen SVP, Chief Scientific Officer	SELL Open market or private sale	Direct	50,000 -72.46%	$200,000 $4.89 P/Share
Oct 01 2021	Lars B. Abrahmsen SVP, Chief Scientific Officer	BUY Exercise of conversion of derivative security	Direct	50,000 +42.02%	$0 $0.92 P/Share

Receive a notification when an Institution or Guru buys or sells APRE shares.

Notify only if

Value

Get notified when an Aprea Therapeutics, Inc. insider buys or sells APRE shares.

Notify only if

Operation

Value

Type

Receive news related to Aprea Therapeutics, Inc.